About ATAI
ATAI is a company based in Munchen (Germany) founded in 2018. It operates as a B2B. ATAI has raised $386.67 million across 6 funding rounds from investors including Galaxy, George Goldsmith and Apeiron Investment Group. ATAI has completed 2 acquisitions, including Kures and Psyber. ATAI operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, Insitro and Ultragenyx, among others.
- Headquarter Munchen, Germany
- Stage Unicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of ATAI
Unlock access to complete
Unlock access to complete
Funding Insights of ATAI
ATAI has successfully raised a total of $386.67M across 6 strategic funding rounds. The most recent funding activity was a Series D round of $157 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ATAI
ATAI has secured backing from 25 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Galaxy, George Goldsmith and Apeiron Investment Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm backed by Christian Angermayer
|
Locked | Locked | Locked | |
|
Thiel Capital is involved in investment and financial activities.
|
Locked | Locked | Locked | |
|
VC firm making sector agnostic investments
|
Locked | Locked | Locked |
Investor details for ATAI
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ATAI
ATAI has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Kures and Psyber.
Investment portfolio details for ATAI
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Opioid-based therapeutics for mood and depression disorders are developed.
|
Locked | Locked | 2015 | Locked | |
|
Website development and digital marketing services are provided by Psyber.
|
Locked | Locked | 2014 | Locked |
Complete acquisition details for ATAI
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - ATAI
Detailed financials for ATAI
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Atai Comparisons
Peer comparison for ATAI
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ATAI
ATAI operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, Insitro and Ultragenyx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of ATAI
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Atai
Complete news archive for ATAI
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ATAI
ATAI was founded in 2018.
ATAI is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
ATAI is a funded company, having raised a total of $386.67M across 6 funding rounds to date.
ATAI a biopharmaceutical company accelerating innovative mental health treatments through providing healthcare solutions, biopharmaceuticals, supporting mental health solutions, and treatment development. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
ATAI's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
ATAI has 25 investors. Key investors include Galaxy, George Goldsmith, Apeiron Investment Group, Thiel Capital, and Woodline Partners.
The valuation of ATAI is $2B as of Mar 2021.